Looking further into past announcements regarding PTX100, Professor H. Miles Prince, Car-T collaborations and products and of course, OmniCAR. I thought i would put this post together as an informative section where the PTS's technology, research and products can be discussed (especially given there are a few new investors of late)...
Some interesting points to note as per my comments below.
Black relates to the PTX100 and Professor H. Miles Prince announcements/comments
Blue relates to Car-T and OmniCAR announcements/comments
11 July 2019– Initiates Phase 1b Clinical trial for PTX100, Prof H. Miles Prince is leadinvestigator. First dose level at 500mg/m²
Who is Professor H. Miles Prince? An internationally recognized Australian Hematologist treatingblood cancers on a daily basis. A highly accomplished professor and current directorships as follows:
Director, Peter MacCallum Cancer Centre Centre for Blood Cell Therapy(1995-) (it isinteresting how many times Peter Mac pops up in PTX dealings, lets dive infurther below…)
Director, Snowdome Foundation (2009-)
Director, The International Society of Cutaneous Lymphoma (2009-)
Director, The Myeloma Foundation Australia
Chairman, The Medical Scientific Advisory Committee to the Myeloma FoundationAustralia (2009-)
Steering Committee, LymphomaHub (2010-)
14 November 2019 – PTX100, First patient dosed on Phase 1b Clinical trial
18 November 2019 – PTX collaboration with Carina Biotech fornext gen Car-T therapies. Carina and PTX to share any IP generated from the collaboration.
22 April2020 – PTX100proceeds to next dose level of 1000mg/m² after acceptable safety in firstcohort at 500mg/m² (note dose level change 6 months after announcement of firstpatient dosing and since trial initiated)
11 May 2020 – PTX negotiate to remove sharing of IP generated from collaboration withCarina Biotech. (from announcement on 18 November 2019).
26 May 2020 – PTX obtain exclusive license for OmniCAR. Main objective …. (quotetaken from 26 May 2020 announcement):
1 June 2020 – Dr ALLEN EBENS joins PTX board as non-executive director. Involved withJuno Therapeutics which is recognized as one of the first Car-T companies… (JunoAcquired for US$9billion in 2018)…. Why did he join… (OmniCAR) (quotetaken from 1 June 2020 announcement):
7 August 2020 – Professor Phillip Darcy joins PTX scientific board….. (quote taken from7 August 2020 announcement) (few extra points highlighted):
12August 2020 – PTX100proceeds to next dose level of 2000mg/m² after acceptable safety in second cohortat 1000mg/m² (note dose level change 4 months after first dose increase initiated)
14 August 2020 – PTX announces collaboration with PeterMacCallum Cancer Centre (Professor H. Miles Prince a current director)….Relating to Car-T research program.
17 December 2020 –Professor H. Miles Prince joins the PTXscientific board… Coincidence or perhaps has a 'belief' about what he is working on (PTX100)...
18 January 2021 – OmniCAR programs announced… A lot to takein in this announcement as it was highly comprehensive (to which I don’t thinkthe market fully understands).
Initially,my thoughts are that Professor Prince has seemingly become more and moreinvolved with PTX which makes me think there is something more than we areseeing here particularly with PTX100.
All in all, we are in for a great show in the months/years ahead with PTX. They are on the cusp of some great technologies which can hopefully make a meaningful and important impact on people suffering from these aggressive (and alot of the time) at the 'end of the rope' cancers.
